Treatment with 5-azacytidin upregulates the expression of CD20 in CD20-negative B cell acute lymphoblastic leukemia: A case report

Experimental Hematology

Volumn 41, Issue 6, 2013, Pages 505-507

  Rahmé, Ramy ^a   Benayoun, Emmanuel ^a   Pautas, Cécile ^a   Cordonnier, Catherine ^a   Wagner Ballon, Orianne ^a   Maury, Sébastien ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; BUSULFAN; CD20 ANTIGEN; CD45 ANTIGEN; CLOFARABINE; CORTICOSTEROID; FLUDARABINE; HLA ANTIGEN; THYMOCYTE ANTIBODY; VALPROIC ACID;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIGEN EXPRESSION; B CELL LEUKEMIA; CANCER MORTALITY; CANCER RECURRENCE; CASE REPORT; DETERIORATION; DONOR LYMPHOCYTE INFUSION; FEMALE; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; LETTER; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; SIBLING; TREATMENT OUTCOME; UPREGULATION;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZACITIDINE; COMBINED MODALITY THERAPY; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; ENZYME INHIBITORS; FATAL OUTCOME; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTONE DEACETYLASE INHIBITORS; HUMANS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENCE; SALVAGE THERAPY; TRANSPLANTATION, HOMOLOGOUS; UP-REGULATION; VALPROIC ACID;

EID: 84878185021     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2013.02.011     Document Type: Letter

References (10)

1. Maury S., Huguet F., Leguay T., et al. Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia. Haematologica 2010, 95:324.
2. Jeha S., Behm F., Pei D., et al. Prognostic significance of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia. Blood 2006, 108:3302.
3. Thomas D.A., O'Brien S., Jorgensen J.L., et al. Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. Blood 2009, 113:6330.
4. Dworzak M.N., Schumich A., Printz D., et al. CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy. Blood 2008, 112:3982.
5. Tomita A., Hiraga J., Kiyoi H., et al. Epigenetic regulation of CD20 protein expression in a novel B-cell lymphoma cell line, RRBL1, established from a patient treated repeatedly with rituximab-containing chemotherapy. Int J Hematol 2007, 86:49.
6. Hiraga J., Tomita A., Sugimoto T., et al. Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance. Blood 2009, 113:4885.
7. Sugimoto T., Tomita A., Hiraga J., et al. Escape mechanisms from antibody therapy to lymphoma cells: downregulation of CD20 mRNA by recruitment of the HDAC complex and not by DNA methylation. Biochem Biophys Res Commun 2009, 390:48.
8. Huguet F., Leguay T., Raffoux E., et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol 2009, 27:911.
9. Bene M.C., Castoldi G., Knapp W., et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia 1995, 9:1783.
10. Gokbuget N., Hoelzer D. Treatment with monoclonal antibodies in acute lymphoblastic leukemia: current knowledge and future prospects. Ann Hematol 2004, 83:201.